Concord Biotech Limited — Q1 FY26 earnings call

Call held 11 Aug 2025

Management summary

Concord Biotech reported a soft Q1 FY26 characterized by 'revenue lumpiness' in the API segment and margin pressure from the newly commercialized Valthera injectable plant. Despite the 5% revenue dip and significant EBITDA contraction, management remains highly bullish on long-term prospects, maintaining their 25% CAGR target. The quarter was marked by strategic milestones, including US FDA approval for Teriflunomide tablets and the launch of the CDMO vertical in the US market.

Highlights

  • Revenue stood at ₹204 crores, a 5% YoY decline due to revenue lumpiness and high base in Q4 FY25.

  • EBITDA margin compressed to 30.1% from 37.7% YoY, primarily due to ₹12-13 crores in commercialization costs for the new Valthera injectable facility.

  • API segment revenue declined 10% YoY to ₹153.8 crores, while Formulation revenue grew 12% YoY to ₹50.2 crores.

  • Management reaffirmed long-term guidance of 25% consolidated revenue CAGR and 35-40% CAGR for the formulation segment.

  • The new Valthera injectable facility is expected to break even by the end of FY26, with a long-term revenue potential of ₹600 crores.

  • CDMO business initiated sales to the US market in Q2 FY26, with a target opportunity size of $40-50 million over the medium term.

  • Successfully cleared inspections from US FDA, EU GMP, and Russian GMP authorities at the Dolka API facility.

Key financials

  1. Revenue ₹204 Cr -5.6%YoY
  2. EBITDA ₹61 Cr -24.7%YoY
  3. EBITDA Margin 30.1%
  4. PAT ₹44 Cr -26.7%YoY
  5. PAT Margin 21.6%
  6. R&D Spend 2.3%

What they filed

Q1 FY27: revenue up 27.9%, net profit up 41.9% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue310 244 430 204 247 −20%278 +14%326 −24%261 +28%
EBITDA137 98 190 61 91 −34%102 +4%122 −36%87 +43%
Net profit99 74 142 43 63 −36%68 −8%90 −37%61 +42%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Segment breakdown

Share of Revenue
₹204 Cr Total
  • API Business ₹153.8 Cr 75.4%
  • Formulation Business ₹50.2 Cr 24.6%

Guidance & targets

Revenue

  • Consolidated Revenue CAGR Revenue · Long-term · High confidence 25%
    So again, when we say a 25% CAGR growth, let me maybe make it a little bit more clearer that Concord has all the ingredients in place to kind of go towards that kind of growth.

    — Ankur Vaid, Joint MD and CEO

  • Formulation Segment CAGR Revenue · Long-term · High confidence 35-40%
    those numbers automatically translate to 40% growth if you're looking at from a formulation, which has a relatively lower base.

    — Ankur Vaid, Joint MD and CEO

  • CDMO Opportunity Size Revenue · Medium-term · Medium confidence $40-50 million
    if we are able to get maybe 4 or 5 opportunities, maybe in totality around $40 million to $50 million. That itself is a sizable opportunity given where we are.

    — Ankur Vaid, Joint MD and CEO

Profitability

  • Valthera Injectable Facility Break-even Profitability · by end of FY26 · Medium confidence Break-even
    Do you expect the facility to break even by the end of FY '26? I would hope so. I would want it to.

    — Ankur Vaid, Joint MD and CEO

Capacity

  • Injectable Facility Revenue Potential Capacity · 5-year period · Medium confidence ₹600 crores
    If you take the injectables, this facility can do close to INR 600 crores.

    — Ankur Vaid, Joint MD and CEO

Risks & concerns

  • Revenue Lumpiness

    medium

    Quarterly fluctuations in API procurement patterns can lead to uneven performance, as seen in the 10% YoY API decline this quarter.

    Management acknowledged

  • High Fixed Costs of New Facilities

    medium

    The Valthera injectable facility is currently weighing on EBITDA margins (760bps impact) and will continue to do so until revenue scales up.

    Both acknowledged

  • Pricing Pressure in New Accounts

    low

    Entering new accounts as a second-source supplier often requires offering price discounts (up to 25% in some cases) to gain traction.

    Management acknowledged

Areas of evasion (1)

  • Specific quarterly guidance for FY26 was avoided, citing business cyclicality.

Q&A highlights

3 direct
Quantification of Valthera Facility Costs Direct
around INR 12 crores to INR 13 crores is the expense that is related to the injectable facility... Out of it, INR 4.27 crores is on account of the employment cost. Power and fuel are around INR 2.77 crores.

Provides clarity on the exact quantum of margin compression caused by the new facility's start-up costs.

Asked by Yagnam Pathak, Asian Market Securities

API Revenue Decline and Pricing Headwinds Direct
So this is primarily on account of... the lumpiness in the business that we have seen because of the heavy quarter 4... we are anticipating that the customers would be having some bit of inventory in their hands.

Management clarifies that the API dip is a volume/timing issue rather than a structural pricing headwind, which is a key concern for pharma investors.

Asked by Vivek Agrawal, Citigroup

Confidence in 25% CAGR Guidance Direct
So on our baseline growth of 18 plus 5% and plus 5% kind of gives us somewhat of a clarity that, yes, 25% can be done... what gives us the comfort is that we have all the right ingredients in place.

Reaffirms management's high conviction in aggressive growth targets despite a weak starting quarter for the fiscal year.

Asked by Maitri Seth, Choice Institutional Equities

2 min read 5 chapters

Detailed narrative

Valthera Facility Weighs on Near-Term Margins

The commercialization of the new injectable facility at Valthera was the primary driver of margin compression this quarter. Management quantified the impact at ₹12-13 crores, including ₹4.27 crores in personnel costs and ₹2.77 crores in power and fuel. Excluding these start-up costs, the EBITDA margin would have been ~37%, consistent with the previous year. The facility is currently at 26% utilization and is targeted to break even by the end of FY26 as domestic and emerging market sales ramp up.

API Segment Faces Quarterly Lumpiness

API revenues declined 10% YoY to ₹153.8 crores, which management attributed to 'revenue lumpiness' following an exceptionally strong Q4 FY25. High inventory levels at customer sites led to softer procurement in Q1. However, management emphasized that pricing remains stable in existing accounts and that the segment's performance should be evaluated on an annualized basis. Capacity utilization at the Dholka API unit remains healthy at 75%.

CDMO and Injectables as Future Growth Engines

Concord is diversifying its revenue mix through the newly launched CDMO vertical and injectable formulations. The CDMO business initiated sales to the US in Q2 FY26, with management identifying a $40-50 million medium-term opportunity (contributing 6-7% to annual growth). The injectable business has launched two products in India, with 10 more in the Phase I pipeline. Long-term, the injectable facility is projected to have a revenue potential of ₹600 crores.

Regulatory Success and Global Expansion

The company successfully cleared multiple high-stakes regulatory inspections, receiving EIR reports from the US FDA for the Dolka facility and passing European and Russian GMP audits. These approvals are critical for ensuring uninterrupted supply to global markets. Furthermore, the incorporation of Stellon Biotech in the US and Concord Lifegen in India marks a strategic shift toward establishing direct commercial footprints and enhancing front-end marketing capabilities.

Reaffirming Aggressive Long-Term Growth

Despite the soft Q1, management remains committed to a 25% consolidated revenue CAGR. This growth is expected to be driven by an 18% baseline growth in the core API business, supplemented by 5-7% contributions from the new CDMO and injectable verticals. The formulation segment is expected to grow even faster at a 35-40% CAGR, albeit from a smaller base, as the company leverages its 30+ fermentation-based API portfolio into finished dosages.

This is an AI-generated summary of a publicly available earnings call transcript.
View original transcript

More Healthcare earnings calls